健保碼及健保價 
See related BCG Immunotherapeutic Immucyst freeze dried vial[巴斯德 BCG 免疫治療劑 乾粉注射劑] information 
製造商 Sanofi Pasteur 
代理/經銷商 Sanofi Pasteur 
成份 Immunotherapeutic BCG (6.6-19.2 x 108 CFU/dose)
適應症 Treatment & prophylaxis of primary or recurrent carcinoma in-situ (CIS) of the urinary bladder & prophylaxis following transurethral resection of primary or recurrent stage Ta &/or T1 papillary tumours, regardless of antecedent intravesical treatment.
用量 Induction therapy 81 mg intravesically once weekly for 6 weeks. After a 6-week pause, 1 intravesical dose given each week for 1-3 weeks. Maintenance therapy 1 dose each week for 1-3 weeks at 6, 12, 18, 24, 30 & 36 months following the initiation of induction treatment.
美國食品藥物管理局之懷孕等級      
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. 
禁忌 Immunosuppressed patients or persons with congenital or acquired immune deficiencies, whether due to concurrent disease (e.g., AIDS, leukemia, lymphoma), cancer therapy (e.g., cytotoxic drugs, radiation), or immunosuppressive therapy (e.g., corticosteroids). Patients with current symptoms or previous history of systemic BCG reaction. Active TB. A Mantoux test should be performed if PPD status is unknown. Treatment should be postponed until resolution of a concurrent febrile illness, UTI, or gross hematuria. 7-14 days should elapse before therapy following biopsy, TUR or traumatic catheterization. Children.
警告 For additional cautionary notes to warn of the potential risk of using the medicine... click to view BCG Immunotherapeutic Immucyst[巴斯德 BCG 免疫治療劑] detailed prescribing infomation
注意事項 Monitored for the presence of symptoms &signs of toxicity after each intravesical treatment. Not recommended for prophylactic treatment following TUR of stage TaG1 papillary tumors unless they are judged to be at high risk of tumor recurrence. Patients with small bladder capacity. Patients at high risk for HIV infection. Pregnancy, lactation.
不良反應 Inflammatory response in the bladder, transient fever, hematuria, urinary frequency, dysuria.
View ADR Monitoring Website[參閱藥物不良反應監測表格]
交互作用 Bone marrow depressants, immunosuppressants, radiotherapy. Antimicrobial therapy.
View more drug interactions with BCG Immunotherapeutic Immucyst[巴斯德 BCG 免疫治療劑]
使用上注意 For caution against possible variation of physical aspect of medicine... click to view BCG Immunotherapeutic Immucyst[巴斯德 BCG 免疫治療劑] detailed prescribing infomation
儲存 View BCG Immunotherapeutic Immucyst[巴斯德 BCG 免疫治療劑] storage conditions for details to ensure optimal shelf-life.
描述 View BCG Immunotherapeutic Immucyst[巴斯德 BCG 免疫治療劑] description for details of the chemical structure and excipients (inactive components).

本商品之市售規格
劑型 包裝 圖片
BCG Immunotherapeutic Immucyst 乾粉注射劑  BCG Immunotherapeutic Immucyst 27 mg x 1's
BCG Immunotherapeutic Immucyst (+ 3 mL diluent) 81 mg x 1's 
 
Manufacturer: Sanofi Pasteur
 
Distributor: Sanofi Pasteur